Bristol Myers Squibb (CELG-RI) Cash from Financing Activities (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Cash from Financing Activities data on file, last reported at -$1.6 billion in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$1.6 billion, down 57.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.9 billion (down 3.85% YoY), and the FY2025 annual result was -$10.3 billion, down 301.83% from the prior year.
• Cash from Financing Activities improved to -$1.6 billion in Q1 2026 per CELG-RI's latest filing, from -$6.0 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $14.6 billion in Q1 2024 and troughed at -$6.0 billion in Q4 2025.
• A 5-year average of -$2.0 billion and a median of -$3.1 billion in 2023 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 580.13% in 2024 and fell as far as 269.8% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$3.2 billion in 2022, then jumped by 129.79% to $967.0 million in 2023, then sank by 269.8% to -$1.6 billion in 2024, then slumped by 267.17% to -$6.0 billion in 2025, then jumped by 74.13% to -$1.6 billion in 2026.
• Business Quant data shows CELG-RI's Cash from Financing Activities at -$1.6 billion in Q1 2026, -$6.0 billion in Q4 2025, and -$1.5 billion in Q3 2025.